SARS-CoV-2 Spike Protein RBD (Beta B.1.351 Variant)
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Spike Protein Receptor-Binding Domain (RBD) is a recombinant protein expressed in Mammalian cells.
The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the Spike Protein and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action.
The Beta (B.1.351) variant was first identified in South Africa. It contains the K417N, E484K and N501Y mutations in the spike protein's receptor-binding domain.
The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the Spike Protein and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action.
The Beta (B.1.351) variant was first identified in South Africa. It contains the K417N, E484K and N501Y mutations in the spike protein's receptor-binding domain.
| Supplier | Abbexa Ltd. |
|---|---|
| Product # | abx620004-1MG |
| Pricing | 1 mg USD $1972.0 |
| Conjugation | Unconjugated |
| Host | Mammalian cells |
| Tested Applications | SDS-PAGE |
| Dry Ice | No |
| Availability | Shipped within 5-10 working days. |
| Note |
|